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Background: Raised serum glucose has been linked to increased risk of many solid cancers. We performed a
meta-analysis to quantify and summarise the evidence for this link.
Methods: Pubmed and Embase were reviewed, using search terms representing serum glucose and cancer.
Inclusion and exclusion criteria focused on epidemiological studies with clear definitions of serum glucose levels,
cancer type, as well as well-described statistical methods with sufficient data available. We used 6.1 mmol/L as the
cut-off for high glucose, consistent with the WHO definition of metabolic syndrome. Random effects analyses were
performed to estimate the pooled relative risk (RR).
Results: Nineteen studies were included in the primary analysis, which showed a pooled RR of 1.32 (95% CI: 1.20 – 1.45).
Including only those individuals with fasting glucose measurements did not have a large effect on the pooled RR
(1.32 (95% CI: 1.11-1.57). A stratified analysis showed a pooled RR of 1.34 (95% CI: 1.02-1.77) for hormonally driven cancer
and 1.21 (95% CI: 1.09-1.36) for cancers thought to be driven by Insulin Growth Factor-1.
Conclusion: A positive association between serum glucose and risk of cancer was found. The underlying biological
mechanisms remain to be elucidated but our subgroup analyses suggest that the insulin- IGF-1 axis does not fully explain
the association. These findings are of public health importance as measures to reduce serum glucose via lifestyle and
dietary changes could be implemented in the context of cancer mortality.
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Diabetes mellitus is a risk factor for many chronic diseases
including cardiovascular disease and cancer. People with
diabetes are 2-fold more likely to die from cancer than those
without [1]. Therefore, it is thought that pre-diagnostic ele-
vated blood glucose levels are associated with risk of cancer
[2-4]. Several epidemiological studies have investigated this
association. The largest being a Korean cohort study of over
one million men and women found a hazard ratio for all
solid cancers of 1.22 (95% CI: 1.16-1.27) for men in the fifth
quintile compared to the first quintile [5].
Despite the growing evidence for an association between
diabetes and carcinogenesis [6], the mechanism by which
raised glucose contributes to risk of cancer is not fully* Correspondence: Danielle.crawley@kcl.ac.uk
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unless otherwise stated.established [7]. The insulin – insulin growth factor (IGF)-1
axis is a commonly suggested pathway. It is thought that
insulin resistance, which impairs the action of insulin and
occurs in individuals with type 2 diabetes or metabolic
syndrome, leads to prolonged hyperinsulinaemia. This de-
creases the production of IGF-binding proteins, which
consequently results in raised IGF-1 levels and cellular
changes leading to carcinogenesis via increased mitosis and
reduced apoptosis [8]. It is, however, important to note that
hyperinsulinemia during the early stages of diabetes may
play a role in carcinogenesis independent of IGF-1 [9].
Another suggested pathway between glucose and risk of
cancer is the reduced hepatic production of sex hormone
binding globulin (SHBG) following prolonged hyperinsuli-
naemia [8]. This leads to an increase of available sex hor-
mones, such as oestrogen and testosterone, which can
drive carcinogenesis in hormonal sensitive cancers like
postmenopausal breast or prostate cancers [8].
Elevated glucose can result in a state of chronic inflam-
mation which changes the cytokine micro-environmentl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Flow chart of study selection.
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(IL-6) [10], tissue necrosis factor alpha (TNF-α) [11,12]
and vascular endothelial growth factor (VEGF) [13]. These
changes can lead to an increase in tumour cell motility,
invasion and even tumour metastasis [14,15].
Finally, glucose may have a direct role in cancer devel-
opment as it is a key nutrient. It is needed for proliferating
cells and several types of tumour cells have been shown to
have up-regulated glucose transporters [16].
Given the above-suggested pathways and the increasing
prevalence of diabetes and cancer, this meta-analysis aims
to summarize and quantify the existing evidence for a link
between raised serum glucose and risk of all solid cancers.
Using data from epidemiological studies on adult partici-
pants whose serum glucose levels and cancer diagnoses
were assessed, this study aims to answer the question
whether there is a higher risk of solid cancer in those with
raised glucose levels, compared to those with normal levels.
Methods
This meta-analysis was conducted following the PRISMA
statement for completing systematic reviews and meta-ana-
lyses [17].
Literature search strategy
A computerised literature search of databases (Pubmed
search followed by an Embase search) to identify full text
and abstracts published within the last fifteen years, which
included only adult human subjects was performed. “Grey
literature” such as abstracts, letters, articles presented at
relevant conferences and meetings, was also reviewed.
The search was done with and without MESH terms
(serum glucose, blood glucose, cancer, neoplasm). We also
conducted cancer-specific searches for prostate, breast, colo-
rectal, oesophageal, gastric, pancreatic, liver, lung, ovarian,
endometrial, cervical, testicular, bladder, melanoma, brain,
thyroid and head and neck cancers. All references of the
selected articles were checked, including hand searches.
The final articles were chosen based on the following set
of inclusion criteria: the publication pertained to an epi-
demiological study which measured circulating serum levels
of glucose (fasting or non fasting); the reference level of
high glucose was clearly defined; risk of a non-fatal solid
cancer (any type) was assessed as an outcome; the analytical
methods were well-described with sufficient and relevant
data available; predominantly non-diseased adult study
populations were used; a minimum of 20 cases were in-
cluded. Studies measuring glucose only after an oral glucose
load were excluded. The literature review and data collec-
tion was conducted by DC and reviewed by MVH.
Initially, titles were reviewed to assess whether they
met inclusion criteria. Titles that indicated the study
met these criteria progressed to an abstract review.
Upon inclusion after this step, the full manuscript wasthoroughly checked to evaluate inclusion and exclusion
criteria. Additional studies were considered from grey lit-
erature and hand searches (N = 18). Unpublished data on
glucose and risk of breast, prostate, and colorectal cancer
was also obtained from the MECAN group, allowing us to
use this large dataset in the analysis of all cancers [18].
Figure 1 provides more detailed information regarding the
exclusion process. More specifically, 12 studies were ex-
cluded because incident cancer risk was not the main out-
come of interest [17,19-29], ten studies did not provide
the data to calculate number of cases with high and nor-
mal glucose levels [4,30-38], 13 studies were using data
which was already used in another included publication
[39-51], one study was cross-sectional and addressed cor-
relations instead of risks [52], one study included less than
20 cases [53], one was not published in English [54], 16
did not provide data on serum glucose levels prior to can-
cer diagnosis [33,55-70], and one study was not available
through our different data resources [71].
The following details were recorded for each study: au-
thor, year of publication, country where study was under-
taken, sex of participants, age range, type of cancer, type
of study, fasting or non fasting glucose measurements and
number of cases and total subjects for each glucose range.
To allow for comparison all values in conventional units
(mg/dl) were converted into SI units (mmol/L) [72].
Statistical methods
The association between serum glucose and cancer risk
was evaluated by calculating the pooled relative risk
(RR) with a random effects model to allow for possible
heterogeneity between studies. A cut-off of > 6.1 mmol/L
was used to define high glucose, consistent with values
used in WHO definition of metabolic syndrome [73].
The included studies all used different cut off points for
Table 1 Summary of study characteristics included in primary analysis









Cases Age range Adjusted for Main finding
Yun et al.
2012 [77]






166 66.4 (mean) Age, BMI OR for 2nd and 3rd tertile compared
to 1st tertile: 1.63 (95% CI: 0.92-2.88)
and 1.70 (95% CI: 0.91-3.18)
Albanes et al.
2009 [78]





100 50-69 Age, BMI OR for 2nd, 3rd, and 4th quartile
compared to 1st quartile: 1.33 (95%
CI: 0.72-2.48), 0.95 (95% CI: 0.46-1.86),
and 1.43 (95% CI: 0.76-2.68)
Chung et al.
2006 [79]




105 35-75 Age, sex, BMI, triglycerides,
cholesterol
OR for 2nd and 3rd tertile compared
to 1st tertile: 2.0 (95% CI: 0.9-4.4) and
3.0 (95% CI: 0.9-9.8)
Jee et al. 2005
Male [5]
Korea Male All Cancers Fasting Not specified Cohort 37759 45.3 (mean) Age, age squared, amount of
smoking, alcohol use
HR for 2nd, 3rd, 4th, and 5th quintile
compared to 1st quintile: 1.01 (95%
CI: 0.99-1.04), 1.13 (95% CI: 1.09-1.17),
1.16 (95% CI: 1.08-1.24), and 1.22
(95% CI: 1.16-1.27)
Jee et al. 2005
Female [5]
Korea Female All Cancers Fasting Not specified Cohort 16074 49.6 (mean) Age, age squared, amount of
smoking, alcohol use
HR for 2nd, 3rd, 4th, and 5th quintile
compared to 1st quintile: 1.02 (95%
CI: 0.99-1.06), 1.03 (95% CI: 0.96-1.10),









128 N/S Age, total calories, BMI OR for 2nd and 3rd tertile compared
to 1st quartile: 0.81 (95% CI: 0.46-
1.44), and 1.68 (95% CI: 1.01-2.80)
Wulaningsih
et al. 2013 [81]
Sweden Both All Cancers Non specified Enzymatically with a
glucose oxidase/
peroxidase method
Cohort 1021 20> Age, gender, socioeconomic status,
fasting,co-morbidities
HR: 1.08 (95% CI: 1.02-1.14) per









284 59.9 (mean) Study centre, menopausal status,
age, time of day of blood collection,
fasting status, phase of menstrual
cycle (pre menopausal)
OR for 2nd, 3rd, and 4th quartile
compared to 1st quartile: 1.01 (95%
CI: 0.58-1.74), 1.59 (95% CI: 0.89-2.83),
and 1.62 (95% CI: 0.89-2.95)
Limburg et al.
2006 [83]





134 50-69 Smoking pack years, BMI, protein
intake, fat intake, fibre intake, alcohol
consumption, caloric intake, history
of DM, occupational physical activity
HR for 2nd, 3rd, and 4th quartile
compared to 1st quartile: 1.19 (95%
CI: 0.58-2.43), 1.95 (95% CI: 0.97-3.91),








169 52-69 Age, years of smoking and BMI HR for 2nd, 3rd, and 4th quartile
compared to 1st quartile: 1.15 (95%
CI: 0.66-2.02), 1.49 (95% CI: 0.86-2.59),
and 1.69 (95% CI: 0.97-2.94)
Yamada 1998
et al. [85]





129 34-73 Age, sex, BMI, smoking, alcohol
consumption
OR for 2nd, 3rd, and 4th quartile
compared to 1st quartile: 1.0 (95% CI:




















Table 1 Summary of study characteristics included in primary analysis (Continued)
Schoen et al.
1999 [86]
USA Both Colorectal Fasting Cohort 102 65 > Age, sex, physical activity
Zhang et al.
2010 [87]





942 N/A Menopausal status, BMI OR: 4.34 (95% CI: 3.48-5.42) for high
versus low serum glucose levels
Gunter et al.
2009 [88]




835 50-79 Age, race, alcohol consumption,
smoking, FHx breast cancer, parity,
age at menarche, age at first childs
birth,use of OCP, NSAIDs, HRT,
educational attainment, endogenous
estrodiol levels, BMI, physical activity
HR for 2nd, 3rd, and 4th quantile
compared to 1st quantile: 1.14 (95%
CI: 0.82-1.59), 0.99 (95% CI: 0.70-1.38),
and 0.92 (95% CI: 0.65-1.29)
Sieri et al.
2012 [89]







356 35-69 Age, education, age at first birth, age
at menarche, parity, FHx breast
cancer, OCP, breastfeeding, alcohol
intake, smoking
OR for 2nd, 3rd, and 4th quartile
compared to 1st quartile: 1.18 (95%
CI: 0.84-1.66), 1.29 (95% CI: 0.89-1.86),
and 1.63 (95% CI: 1.14-2.32)
Gunter et al.
2008 [44]




438 50-79 Age HR for 2nd, 3rd, and 4th quantile
compared to 1st quantile: 0.94 (95%
CI: 0.66-1.34), 0.91 (95% CI: 0.63-1.30),
and 1.16 (95% CI: 0.83-1.63)
Van Hemelrijck
et al. 2011 [90]




Cohort 958 55.4 (mean) Age, gender, creatinine, triglycerides,
total cholesterol, fasting status, SES
HR for 2nd, 3rd, and 4th quartile
compared to 1st quartile: 0.97 (95%
CI: 0.77-1.21), 1.09 (95% CI: 0.88-1.35),
and 1.19 (95% CI: 0.97-1.46)
Van Hemelrijck
et al. 2011 [91]




Cohort 5112 20-80 Fasting status,triglyceride and total
cholesterol quartile , SES, time btw
measurement and cohort entry
HR for 2nd, 3rd, and 4th quartile
compared to 1st quartile: 0.93 (95%
CI: 0.86-1.01), 0.93 (95% CI: 0.85-1.01),
and 0.87 (95% CI: 0.81-0.94)
Chao et al.
2011 [92]




124 30-65 Age, smoking, alcohol consumption,
FHx of HCC, HBV viral load, HCV
genotype ,HbeAg status, BCP double
mutations
HR for 2nd and 3rd tertile compared
to 1st tertile: 1.40 (95% CI: 0.80-2.45)









Cohort 18621 44.7 (mean) Age, BMI, smoking status HR for 2nd, 3rd, 4th, and 5th quintile
compared to 1st quintile: 1.07 (95%
CI: 0.90-1.25), 1.10 (95% CI: 0.93-1.29),






Female All Cancers Mixed Cohort 11664 45 (mean) Age, BMI, smoking status HR for 2nd, 3rd, 4th, and 5th quintile
compared to 1st quintile: 0.87 (95%
CI: 0.70-1.07), 0.90 (95% CI: 0.73-1.10),
1.18 (95% CI: 0.97-1.42), and 1.29
(95% CI: 1.07-1.59)
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quintiles. For the sake of this analysis all data was
dichotomised into ‘high’ and ‘normal’ as close to the
6.1 mmol/L cut off as possible by combining groups
above and below this level.
An initial meta-analysis was performed using all stud-
ies. Potential heterogeneity was assessed with weighted
forest plots, which display the relative risk estimate of
cancer depending on glucose level. Potential publication
bias was assessed with a contour enhanced funnel plot,
as well as Beggs Test [41,42]. We also performed strati-
fied analyses by study type and sex. We then conducted
cancer-specific analyses for prostate, breast, and colorec-
tal cancer, as these were the most commonly investi-
gated cancers. We also conducted a secondary analysis
excluding those studies which did not specify the fasting
status of the glucose samples. Given the suggested com-
plex aetiology between diabetes, glucose, and cancer, we
additionally conducted stratified analyses based on po-
tential underlying mechanisms – below referred to asFigure 2 Forest plot for studies comparing risk of cancer by serum gl
reference category.hormone-driven and IGF-1-driven [74,75]. Although the
identification of which cancers are driven by the IGF-1 axis,
is not entirely elucidated, the cancers for which the most
consistent supporting evidence is available are prostate,
colorectal and breast cancer [9,52,75,76]. Hence, here we
considered these as ‘IGF-1 driven’ cancers. Breast, endomet-
rial and prostate cancers were also combined for a separate
subgroup of ‘hormone driven’ cancers [23,30,55]. All ana-
lyses were performed on STATA version 12.0.
Results
The Pubmed search resulted in a total of 1,473 studies, 45
of which were deemed as initially relevant. A further 11
were identified via an Embase search and 18 from hand
searches and grey literature, resulting in a total of 74 poten-
tially relevant papers. Using the above-defined criteria, 55
were excluded (Figure 1).
A total of 19 studies were included in the primary analysis:
six cohort, six case cohort, three hospital-based case–con-
trol, and four nested case–control studies. Nine studies wereucose levels with serum glucose < 6.11 mmol/L as the
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Three studies presented data on all solid cancers, five on
colorectal cancer, four on prostate cancer, two on breast
cancer, two on endometrial cancer and one paper each for
pancreatic, renal and hepatocellular cancers (Table 1).
The random effects analysis comparing overall cancer
risk by serum glucose levels showed a pooled relative risk
(RR) of 1.32 (95% CI: 1.20 – 1.45) for high versus normal
levels of serum glucose (Figure 2). The I2 statistic showed
heterogeneity (I2 = 92%; P < 0.05), even though every indi-
vidual estimate indicated a positive association. Hence, we
conducted a ‘remove one’ analysis to gauge each study’s
impact; the I2 statistic did not fall below 85%. Next, we
conducted a sensitivity analysis using studies which in-
cluded ‘all cancers’ as the outcome versus those with site
specific outcomes. The heterogeneity remained high and
the RR did not change drastically. When looking at “All
cancers” as an outcome, the RR was 1.21(95% CI: 1.09-
1.34) with and I2 of 92%. When combining all site-specific
cancers as an outcome, the RR was 1.38 (95% CI: 1.16-
1.63) with an I2 of 92%. Tumour-specific analyses were
performed for the three most commonly studied cancers
and resulted in pooled relative risks of 1.09 (95% CI: 0.95-Figure 3 Forest plots. a: Forest plots for cohort studies comparing risk of
the reference category. b: Forest plots for nested case–control and case-co
serum glucose < 6.11 mmol/L as the reference category. c: Forest plots for
glucose levels with serum glucose < 6.11 mmol/L as the reference category1.25), 1.35 (95% CI: 1.21-1.51) and 1.14 (95% CI: 1.04-
1.26), for breast, colorectal and prostate cancer, respec-
tively. The related I2 statistic was 74% for breast, 57%
for colorectal, and 53% for prostate.
A stratified analysis by study type showed similar pooled
RRs for cohort studies, case-cohort/nested case–control
studies and hospital-based case–control studies (Figure 3):
1.24 (95% CI: 1.13-1.37), 1.29 (95% CI: 1.11-1.51), and
1.64 (95% CI: 1.11-2.43). The I2 statistic was 92%, 76%,
and 93%, respectively (Figure 4).
The overall pooled RR was 1.17 (95% CI: 1.09-1.25) for
men and 1.32 for women (95% CI: 1.06-1.63). Studies
where it was not possible to stratify by sex showed a
pooled RR of 1.55 (95% CI: 1.40-1.71). The I2 statistic for
these sex-stratified analyses was 48% for men, 96%, for
women and 19% where it was not possible to stratify by
sex. Including only those with fasting glucose measure-
ments did not have a large effect on the pooled RR either
(RR: 1.32 (95% CI: 1.11-1.57). The I2 statistic was 92%.
The pooled RR for hormonally driven cancers was 1.34
(95% CI: 1.02-1.77; I2: 96%) versus 1.41 (95% CI: 1.20-1.66;
I2: 69%) for the non-hormonally driven cancers. IGF-1-
driven cancers showed a pooled RR of 1.21 (95% CI: 1.09-cancer by serum glucose levels with serum glucose < 6.11 mmol/L as
hort studies comparing risk of cancer by serum glucose levels with
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Figure 4 Contour enhanced funnel plot for meta-analysis comparing risk of cancer by serum glucose levels with serum glucose < 6.11 mmol/L
as the reference category.
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those not thought to be driven by IGF.
When assessing publication bias, the funnel plot showed
an area of missing studies which includes regions of both
low and high statistical significance suggesting that both
studies that showed a non-significantly and significantly
inverse association between glucose and cancer were
missing. Therefore, under the assumption that studies are
being suppressed because of a mechanism based on two-
sided p-values, publication bias cannot be accepted as the
only cause of funnel asymmetry.
Discussion
This is the first meta-analysis examining the association
of serum glucose and cancer risk. We found a consistent
positive association, which was not altered strongly by
sex, study type, or cancer type.
As previously described, several molecular mechanisms
have been postulated in an effort to explain the association
between glucose and carcinogenesis. The insulin – IGF-1
axis is the most commonly suggested pathway [93]. Our
results showed a weaker association for IGF-1 driven can-
cers than the overall association or non-hormonally driven
cancers, suggesting that if the insulin- IGF- 1 axis does
play a role it is likely to be as part of a more complex mo-
lecular mechanism.
Another proposed mechanism is an increased avail-
ability of sex hormones caused by a reduction of SHBG
in the presence of hyperinsulinaemia [7,94]. However,our meta-analysis showed a similar association between
elevated serum glucose and risk of hormonally and non-
hormonally driven cancers. This suggests that this is not
the only underlying mechanism for the link between
glucose and cancer. It is possible that other mechanisms,
i.e. chronic inflammation [10-12] or direct actions of
glucose [16], may also be playing a role.
To our knowledge this is the first comprehensive
meta-analysis looking at epidemiological studies of se-
rum glucose levels and cancer risk. Existing meta-
analyses to date focused on the association between
serum glucose levels and a specific type of cancer [4,76].
A breast cancer-specific study including ten cohort stu-
dies found that the association between serum glucose
levels and risk of breast cancer was small in non-
diabetic subjects (pooled RR: 1.11 (95% CI: 0.98-1.25)
[4]. The direction of this study is consistent with our
findings, however our meta-analysis focused on high
serum glucose levels as defined by the WHO definition
for metabolic syndrome so that we also included poten-
tial diabetic subjects. Thus, when investigating serum
levels of glucose, it is also important to consider dia-
betes. A bladder cancer-specific study showed that dia-
betes was associated with a 30% increased risk (95% CI:
1.18-1.43), which is consistent with the direction of the
association found for serum glucose and cancer in our
meta-analyses [76]. Other cancer types which also show
a positive association with diabetes include pancreatic,
endometrial, breast and colorectal cancer [20-22,95],
Crawley et al. BMC Cancer 2014, 14:985 Page 8 of 11
http://www.biomedcentral.com/1471-2407/14/985however an inverse association has been observed for
prostate cancer [91]. The latter must be interpreted with
caution as diabetics have higher morbidity and mortality
from other diseases. There may be competing risks masking
their risk of prostate cancer [96]. However, it is important to
note that diabetes is a slightly different exposure than serum
levels of glucose as diabetic treatments may normalise glu-
cose levels and potentially also affect risk of cancer [43].
We made every effort to include all relevant publications
available to date through various sources, including grey
literature, and the two main online databases (Pubmed and
Embase). We were able to also access unpublished data
from the MECAN group enabling us to include this large
cohort of over 500,000 subjects [18]. In addition, clearly de-
fined objective criteria for exposure, outcome, and other
study characteristics were specified a priori. One limitation
of our study is the heterogeneity between the different
categorization methods for glucose ranges across the in-
clude studies. We tried to overcome this by combining the
different categories as similarly as possible and believe this
cannot significantly affect our findings. Nevertheless, this
made it not possible in the current meta-analysis to make a
distinction between pre-diabetes and diabetes. The overall
results showed a rather large amount of heterogeneity, as
suggested by the I2 statistic. All of our sensitivity and sub-
group analyses showed consistent findings in terms of dir-
ection of the association, while the heterogeneity remained
high. Only when we conducted tumour specific analysis,
the I2 statistic reduced. This suggests that heterogeneity is
most likely explained by combining studies with different
outcomes. However, the consistent finding of a positive as-
sociation in all our analyses supports the robustness of our
findings. Six of the studies included, either had mixed or
did not specify fasting status. However, exclusion of these
studies did not alter the association observed. A further
limitation is the lack of information regarding the diagnosis
of diabetes, use of oral hypoglycaemics or insulin in those
included in the studies. Future research including adjust-
ment for components such as age, cancer treatment, dia-
betes (or its treatments), or BMI would be useful in
confirming the importance of raised glucose in carcinogen-
esis. All studies included were soundly designed and exe-
cuted epidemiological studies, which clearly defined their
methodology. However, the size of the studies did vary
considerably. The two largest studies [5,18] did account for
well over half of the cases included, but they represent a
Korean and European population which we believe can be
broadly applicable to all patient populations. Limitations
reported by the individual studies overlap widely. They in-
clude, having only localised cancer as an outcome, small
sample size, specific demographic groups only (i.e. smokers
only), lack of information on diabetes and obesity and all
but one study [81] used single measurements of glucose
for their analysis.Conclusions
A positive association was found between serum glucose
levels and risk of cancer. The heterogeneity observed
between studies calls for more translational studies investi-
gating how serum glucose is associated with carcinogen-
esis. However, given there were seven million deaths from
cancer worldwide in 2011 and it is estimated that more
than a third were attributable to modifiable risk factors
[97], these findings are of public health importance as
measures to reduce serum glucose via lifestyle and dietary
changes could be implemented to reduce risk of cancer.
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